Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.